Chemotherapy activates inflammasomes to cause inflammation-associated bone loss

Keyphrases

• Inflammation 100%
• Chemotherapy 100%
• Inflammasome 100%
• Bone Loss 100%
• Doxorubicin 100%
• NOD-like Receptor Protein 3 (NLRP3) 66%
• Interleukin-1β 33%
• Wild Mice 33%
• Mouse Model 33%
• Hematological Malignancies 33%
• Neutrophils 33%
• Macrophages 33%
• Survival Rate 33%
• Serum Levels 33%
• Cancer Patients 33%
• Multiple Organs 33%
• Adjuvant Therapy 33%
• Drug Class 33%
• Interleukin-18 (IL-18) 33%
• Osteoclast 33%
• Melanoma 33%
• Leukopenia 33%
• Solid Malignancies 33%
• NLRP3 Inflammasome 33%
• Cytokine Secretion 33%
• Pyroptosis 33%
• Cell-free DNA (cfDNA) 33%
• Inflammatory Cell Death 33%
• NETosis 33%
• Tumor-free 33%
• Off-target Effects 33%
• Antineoplastic Drugs 33%
• Danger-associated Molecular Patterns 33%
• Cell Demise 33%
• Massive Bone Loss 33%
• Free ATP 33%
• Danger Level 33%

Pharmacology, Toxicology and Pharmaceutical Science

• Chemotherapy 100%
• Inflammation 100%
• Inflammasome 100%
• Doxorubicin 100%
• Cytokine 66%
• Wild Type Mouse 33%
• Neoplasm 33%
• Malignant Neoplasm 33%
• Hematologic Malignancy 33%
• Mouse Model 33%
• Survival Rate 33%
• Adenosine Triphosphate 33%
• Melanoma 33%
• Antiinfective Agent 33%
• Leukopenia 33%
• Interleukin 18 33%
• Pyrin 33%
• Pyroptosis 33%

Immunology and Microbiology

• Osteolysis 100%
• Inflammasome 100%
• AIM2 50%
• Cytokine 25%
• Mouse Model 25%
• Macrophage 25%
• Cell Death 25%
• Wild Type Mouse 25%
• Interleukin-1 25%
• Blood Level 25%
• Neutrophil 25%
• Interleukin 18 25%
• Osteoclast 25%
• Survival Rate 25%
• Inflammatory Cell 25%
• Skeleton 25%
• NLRP3 Inflammasome 25%
• Cytokine Release 25%
• Pyroptosis 25%
• Pyrin Domain 25%
• NETosis 25%
• DAMPs 25%